Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Thu, 3-Sep 4:30 PM ET)
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 5-Aug 4:05 PM ET)
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Globe Newswire (Tue, 4-Aug 4:05 PM ET)
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Tue, 14-Jul 9:00 PM ET)
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Globe Newswire (Mon, 29-Jun 8:30 AM ET)
Market Chameleon (Thu, 5-Mar 6:06 AM ET)
Tenaya Therapeutics Set to Spotlight Genetic Heart Therapies at H.C. Wainwright Conference
Market Chameleon (Fri, 10-Oct 7:10 AM ET)
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Tenaya Therapeutics trades on the NASDAQ stock market under the symbol TNYA.
As of September 9, 2026, TNYA stock price climbed to $0.67 with 881,047 million shares trading.
TNYA has a beta of 1.80, meaning it tends to be more sensitive to market movements. TNYA has a correlation of 0.04 to the broad based SPY ETF.
TNYA has a market cap of $145.39 million. This is considered a Micro Cap stock.
Last quarter Tenaya Therapeutics reported $1 million in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-9 million and missed earnings estimates by -$.13.
In the last 3 years, TNYA traded as high as $7.01 and as low as $.36.
The top ETF exchange traded funds that TNYA belongs to (by Net Assets): VTI, VXF, PRFZ, QQQS, IBBQ.
TNYA has underperformed the market in the last year with a price return of -52.1% while the SPY ETF gained +18.7%. TNYA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.4% and -4.5%, respectively, while the SPY returned +3.4% and -0.4%, respectively.
TNYA support price is $.64 and resistance is $.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNYA shares will trade within this expected range on the day.
